EUVIMEDEUVIMED entdecken
Crossref

PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast

Haley N Corbin, Azfar Neyaz, Terri E Jones, Beth Z Clark iD, Jing Yu iD, Jeffrey L Fine iD, Ivy John, Rohit Bhargava iD

American Journal of Clinical Pathology · 2025

DOI: 10.1093/ajcp/aqaf084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2025. Verfasst von Haley N Corbin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. Hauptthemen laut MEDLINE: Hemangiosarcoma, Breast Neoplasms, Biomarkers, Tumor, Antigens, Neoplasm. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We examined the utility of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry (IHC) in distinguishing breast angiosarcoma from benign or atypical vascular lesions (AVLs) of the breast.

Methods

There were 26 breast angiosarcomas (24 radiation related and 2 primary), 6 radiation-related AVLs of the breast, and 16 other benign vascular lesions of the breast retrieved from our institutional archive and stained with PRAME IHC.

Results

Twenty-four of 26 (92%) breast angiosarcomas were positive for PRAME with moderate to strong staining intensities (median HScore, 255 [range, 90-300]), while 0 of 22 benign or atypical vascular lesions of the breast were PRAME positive (sensitivity, 92.3% [95% CI, 75.9%-98.6%]; specificity, 100% [95% CI, 85.1%-100%]); c-MYC was positive in all angiosarcoma cases but showed weak staining in several cases (median HScore, 155 [range, 30-280]). PRAME was negative in 1 of 2 primary angiosarcomas and negative in only 1 of 24 secondary angiosarcomas of the breast. None of the benign or atypical vascular lesions was stained with PRAME.

Conclusions

It appears that PRAME expression occurs in a high proportion of radiation-related angiosarcomas and not in benign breast vascular lesions or AVLs. PRAME IHC is diagnostically useful in distinguishing benign from malignant vascular proliferations in patients with a history of radiation to the breast.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiosarcomaBreast NeoplasmsBiomarkers, TumorAntigens, NeoplasmNeoplasms, Radiation-InducedHumansFemaleImmunohistochemistryDiagnosis, DifferentialMiddle AgedAgedAdultAged, 80 and overSensitivity and SpecificityBreast

Stichwörter der Autor:innen

AVLMYCPRAMEangiosarcomabreastimmunohistochemistryradiation-associated

Substanzen

PRAME protein, humanBiomarkers, TumorAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.
  • Division of Breast, GYN, and Perinatal Pathology, UPMC Magee-Womens Hospital, Pittsburgh, PA, United States.

ORCID-Profile: Beth Z Clark, Jing Yu, Jeffrey L Fine, Rohit Bhargava

Zitieren

APA

Corbin, H. N., Neyaz, A., Jones, T. E., Clark, B. Z., Yu, J., Fine, J. L., John, I., & Bhargava, R. (2025). PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqaf084

Vancouver

Corbin HN, Neyaz A, Jones TE, Clark BZ, Yu J, Fine JL, et al. PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast. American Journal of Clinical Pathology. 2025. doi:10.1093/ajcp/aqaf084

BibTeX
@article{Corbin2025,
  author = {Corbin, Haley N and Neyaz, Azfar and Jones, Terri E and Clark, Beth Z and Yu, Jing and Fine, Jeffrey L and John, Ivy and Bhargava, Rohit},
  title = {PRAME immunohistochemistry distinguishes breast secondary angiosarcoma from benign and atypical vascular lesions of the breast},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  doi = {10.1093/ajcp/aqaf084}
}
Kostenlos starten →